JP2005510535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510535A5 JP2005510535A5 JP2003546836A JP2003546836A JP2005510535A5 JP 2005510535 A5 JP2005510535 A5 JP 2005510535A5 JP 2003546836 A JP2003546836 A JP 2003546836A JP 2003546836 A JP2003546836 A JP 2003546836A JP 2005510535 A5 JP2005510535 A5 JP 2005510535A5
- Authority
- JP
- Japan
- Prior art keywords
- delivery agent
- dosage form
- cromolyn sodium
- mass
- cromolyn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000265 cromoglicic acid Drugs 0.000 claims description 51
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 18
- 229960001340 histamine Drugs 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 7
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 49
- 229940124447 delivery agent Drugs 0.000 claims 32
- 239000006186 oral dosage form Substances 0.000 claims 23
- 238000000034 method Methods 0.000 claims 19
- 102000004127 Cytokines Human genes 0.000 claims 7
- 108090000695 Cytokines Proteins 0.000 claims 7
- 210000003630 histaminocyte Anatomy 0.000 claims 7
- 238000010521 absorption reaction Methods 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 229910052708 sodium Inorganic materials 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 150000001345 alkine derivatives Chemical class 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 239000008184 oral solid dosage form Substances 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- -1 pyrrolo Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 description 3
- 239000013566 allergen Substances 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
Images
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33439501P | 2001-11-29 | 2001-11-29 | |
| US60/334,395 | 2001-11-29 | ||
| US38491602P | 2002-05-24 | 2002-05-24 | |
| US60/384,916 | 2002-05-24 | ||
| PCT/US2002/038247 WO2003045331A2 (en) | 2001-11-29 | 2002-11-29 | Formulations for oral administration of cromolyn sodium |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005510535A JP2005510535A (ja) | 2005-04-21 |
| JP2005510535A5 true JP2005510535A5 (enExample) | 2006-02-02 |
| JP5196701B2 JP5196701B2 (ja) | 2013-05-15 |
Family
ID=26989179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003546836A Expired - Fee Related JP5196701B2 (ja) | 2001-11-29 | 2002-11-29 | クロモリンナトリウムの経口投与用製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20040259952A1 (enExample) |
| EP (1) | EP1461031B1 (enExample) |
| JP (1) | JP5196701B2 (enExample) |
| AU (1) | AU2002352974A1 (enExample) |
| CA (1) | CA2466863A1 (enExample) |
| WO (1) | WO2003045331A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050209141A1 (en) * | 2003-10-17 | 2005-09-22 | Silver Randi B | Mast cell-derived renin |
| EP1745007A2 (en) | 2004-04-16 | 2007-01-24 | Emisphere Technologies, Inc. | 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents |
| NZ551196A (en) * | 2004-05-14 | 2010-08-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
| NZ551597A (en) * | 2004-05-19 | 2010-11-26 | Emisphere Tech Inc | Topical cromolyn formulations |
| CN1968699B (zh) | 2004-05-19 | 2010-12-15 | 爱密斯菲尔科技公司 | 阿昔洛韦制剂 |
| AU2005321803B2 (en) | 2004-12-29 | 2012-02-09 | Emisphere Technologies, Inc. | Pharmaceutical formulations of gallium salts |
| US8110547B2 (en) | 2005-01-12 | 2012-02-07 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| WO2007052398A1 (ja) * | 2005-11-01 | 2007-05-10 | Reverse Proteomics Research Institute Co., Ltd. | アレルギー疾患の治療に有用な化合物をスクリーニングする方法 |
| GB0522566D0 (en) * | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
| US20070249727A1 (en) * | 2006-04-21 | 2007-10-25 | The Proctor & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
| US10022339B2 (en) | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| US9364502B2 (en) | 2006-06-28 | 2016-06-14 | Emisphere Technologies, Inc. | Gallium nitrate formulations |
| US8445437B2 (en) * | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
| CN101808642B (zh) * | 2007-09-28 | 2012-05-02 | 布里格海姆妇女医院公司 | 肥大细胞稳定剂治疗肥胖症 |
| US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| CN105061376A (zh) * | 2009-01-29 | 2015-11-18 | 通用医疗公司 | 色甘酸衍生物以及成像和治疗的相关方法 |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| US20110039930A1 (en) | 2009-08-03 | 2011-02-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
| US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| MX345501B (es) | 2010-12-16 | 2017-02-02 | Novo Nordisk As | Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico. |
| KR101972836B1 (ko) | 2011-04-12 | 2019-04-29 | 노보 노르디스크 에이/에스 | 이중 아실화된 ｇｌｐ-1 유도체 |
| US8843456B2 (en) | 2011-12-06 | 2014-09-23 | International Business Machines Corporation | Database table compression |
| HRP20190489T1 (hr) | 2012-03-22 | 2019-05-03 | Novo Nordisk A/S | Pripravci koji sadrže sredstvo za unošenje i njihova priprava |
| WO2013139695A1 (en) | 2012-03-22 | 2013-09-26 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
| EP2827885B1 (en) | 2012-03-22 | 2018-08-15 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
| US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| EP2911664B1 (en) | 2012-10-25 | 2019-05-08 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| WO2014160683A2 (en) * | 2013-03-27 | 2014-10-02 | Scpharmaceuticals, Llc | Combination therapy for subcutaneous administration of glycopeptide antibiotics |
| SMT201800492T1 (it) | 2013-05-02 | 2018-11-09 | Novo Nordisk As | Dosaggio orale di composti di glp-1 |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| AU2014340182B2 (en) | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| EP3068375B1 (en) * | 2013-11-11 | 2020-04-22 | Harish, Ziv | Formulations and methods for prevention and treatment of oral allergy syndrome |
| EP3725311A1 (en) | 2014-02-10 | 2020-10-21 | Respivant Sciences GmbH | Methods for the treatment of lung diseases with mast cell stabilizers |
| EP3653207A1 (en) | 2014-02-10 | 2020-05-20 | Respivant Sciences GmbH | Mast cell stabilizers treatment for systemic disorders |
| JP6925969B2 (ja) * | 2015-02-09 | 2021-08-25 | エンテラ バイオ エルティーディー． | 医薬組成物 |
| EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| KR102393596B1 (ko) * | 2016-04-22 | 2022-05-04 | 리셉터 홀딩스, 인크. | 속효성 식물-계 의약 화합물 및 영양 보충제 |
| IL321113A (en) | 2016-08-17 | 2025-07-01 | Entera Bio Ltd | Formulations for oral administration of active agents |
| CN110139646A (zh) | 2016-08-31 | 2019-08-16 | 瑞思皮万特科学有限责任公司 | 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物 |
| CA3033079A1 (en) | 2016-08-31 | 2018-03-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| WO2018067341A1 (en) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
| EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
| KR20190103302A (ko) * | 2017-01-03 | 2019-09-04 | 리셉터 홀딩스, 인크. | 의약 화합물 및 영양 보충제 |
| KR20210070232A (ko) | 2017-07-20 | 2021-06-14 | 아즈테라피즈 인코포레이티드 | 크로몰린 나트륨 및 이부프로펜의 분말화된 제형 |
| EP3720429A4 (en) * | 2017-12-04 | 2021-09-15 | The General Hospital Corporation | COMPOSITIONS BASED ON CROMOGLICIC ACID AND RELATED PROCESSES |
| EP4299118A3 (en) | 2018-02-02 | 2024-04-10 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| CA3105392A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Powdered formulations of cromolyn sodium and .alpha.-lactose |
| UA122811C2 (uk) * | 2018-08-10 | 2021-01-06 | Наталія Миколаївна Тихонівська | Фармацевтична композиція |
| WO2020097686A1 (en) * | 2018-11-14 | 2020-05-22 | Holman Pharmaceuticals Pty Ltd | Compositions and uses thereof |
| AR117118A1 (es) | 2018-11-19 | 2021-07-14 | Receptor Holdings Inc | Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides |
| EP3893945A4 (en) | 2018-12-10 | 2022-11-30 | The General Hospital Corporation | CROMOGLYC ESTERS AND THEIR USES |
| US12458622B2 (en) | 2020-04-06 | 2025-11-04 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| US11986492B2 (en) * | 2022-09-21 | 2024-05-21 | Ashley Wolchina Allison | Oral supplement for preventing colic in horses |
| CN116509836A (zh) * | 2023-03-23 | 2023-08-01 | 中山万汉制药有限公司 | 色甘酸钠－季铵盐复合物及其制备方法与用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6281380A (ja) * | 1985-10-04 | 1987-04-14 | Kyoto Yakuhin Kogyo Kk | クロモグリク酸誘導体、その製造法および抗アレルギ−剤 |
| US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| US5447728A (en) * | 1992-06-15 | 1995-09-05 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
| JPH06281380A (ja) | 1993-03-26 | 1994-10-07 | Hisaka Works Ltd | プレート式熱交換器用ガスケット |
| JP4361601B2 (ja) * | 1993-04-22 | 2009-11-11 | エミスフェアー・テクノロジーズ・インク | 経口薬剤移送組成物およびその方法 |
| US5643957A (en) * | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| JP3124041B2 (ja) * | 1996-08-30 | 2001-01-15 | 京都薬品工業株式会社 | アレルギー性皮膚炎治療剤 |
| JP4975201B2 (ja) | 1997-02-07 | 2012-07-11 | エミスフェアー・テクノロジーズ・インク | 化合物及び活性剤を送達するための組成物 |
| US5888529A (en) * | 1997-03-28 | 1999-03-30 | The Regents Of The University Of California | Ileus treatment method |
| US5863944A (en) * | 1997-04-30 | 1999-01-26 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5952353A (en) * | 1997-09-19 | 1999-09-14 | Auburn University | Treating/preventing heart failure via inhibition of mast cell degranulation |
| EP1049459B1 (en) * | 1998-01-20 | 2009-04-22 | Applied Analytical Industries, Inc. | Oral liquid compositions |
| ES2242412T3 (es) * | 1998-07-27 | 2005-11-01 | Emisphere Technologies, Inc. | Compuestos que permiten administrar agentes activos y composiciones a base de estos compuestos. |
| CA2339765C (en) * | 1998-08-07 | 2009-04-28 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| GB9824604D0 (en) * | 1998-11-11 | 1999-01-06 | Hewlett Healthcare Limited | Treatment of allergic conditions |
| MXPA01008611A (es) * | 1999-02-26 | 2003-06-24 | Emisphere Tech Inc | Compuestos y composiciones para suministrar agentes activos. |
| NZ534409A (en) * | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| AU2622301A (en) * | 1999-11-05 | 2001-05-14 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| ES2298168T3 (es) * | 1999-12-16 | 2008-05-16 | Emisphere Technologies, Inc. | Compuestos y composiciones para suministrar agentes activos. |
| CA2292902C (en) * | 1999-12-24 | 2012-12-18 | Alain Cadieux | Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases |
| JP4879433B2 (ja) * | 2000-01-13 | 2012-02-22 | エミスフェアー・テクノロジーズ・インク | 活性剤を送達するための化合物および組成物 |
| US6225356B1 (en) * | 2000-01-20 | 2001-05-01 | Jones, Iii Tudor | Cromolyn sodium containing composition and method of treatment for vilvar vestibulitis interstitial cystitis vukvar vaginitis and vaginitis dynea |
| AU2001245273A1 (en) * | 2000-02-15 | 2001-08-27 | Board Of Trustees Of The University Of Arkansas | Recombinant vector expressing a beta2-adrenergic receptor and use in treating airway and vascular diseases |
| US7351741B2 (en) * | 2000-06-29 | 2008-04-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| BR0114799A (pt) * | 2000-09-06 | 2003-12-30 | Emisphere Tech Inc | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos |
-
2002
- 2002-11-29 AU AU2002352974A patent/AU2002352974A1/en not_active Abandoned
- 2002-11-29 JP JP2003546836A patent/JP5196701B2/ja not_active Expired - Fee Related
- 2002-11-29 EP EP02789934.3A patent/EP1461031B1/en not_active Expired - Lifetime
- 2002-11-29 CA CA002466863A patent/CA2466863A1/en not_active Abandoned
- 2002-11-29 WO PCT/US2002/038247 patent/WO2003045331A2/en not_active Ceased
- 2002-11-29 US US10/497,286 patent/US20040259952A1/en not_active Abandoned
-
2008
- 2008-04-16 US US12/103,821 patent/US8513300B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005510535A5 (enExample) | ||
| JPS6143112A (ja) | 精神性欲機能障害治療剤 | |
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| JP2005515966A5 (enExample) | ||
| KR20190055057A (ko) | 알코올 사용 장애의 치료용 조성물, 장치 및 방법 | |
| CA3043028A1 (en) | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions | |
| JP2019031551A (ja) | 女性胃不全麻痺に関係する症状の処置 | |
| US20220151960A1 (en) | Treatment of symptoms associated with female gastroparesis | |
| JP2012533559A (ja) | アセトアミノフェンの治療効果を改善するためのｎ−アセチルシステイン組成物および方法 | |
| AU2008259864B2 (en) | Methods and compositions for administration of Oxybutynin | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| JP2005512946A5 (enExample) | ||
| US20100105685A1 (en) | S-Nitrosothiol Compounds and Related Derivatives | |
| US20240408004A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders | |
| CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| EP3897579A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders | |
| WO2026013001A1 (en) | Phosphatidylinositol 4-kinase beta inhibitor compositions for treating human rhinovirus infection | |
| JPH01501708A (ja) | アミノ酸の経鼻投与 | |
| JP2004175786A (ja) | Ｉ型アレルギー疾患治療用組成物 | |
| JPS6040409B2 (ja) | ピペリジルアセチルアミノ安息香酸エチルを含有する抗動脈硬化症剤 | |
| JPH0278618A (ja) | 抗アレルギー剤 |